Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, has inaugurated its cutting-edge Biopharma Capability Center in Hyderabad. This strategic move reinforces Agilent’s commitment to India’s thriving biopharma sector and aligns with its global three-to-five-year growth vision.
A Major Boost to India’s Life Sciences Ecosystem
The center was officially inaugurated by Telangana’s Minister for IT, Electronics, Communications, and Industries, Duddila Sridhar Babu, in the esteemed presence of Agilent’s global CEO, Padraig McDonnell. Designed to support the entire drug development lifecycle, the center will empower scientists, researchers, and companies with advanced instrumentation, hands-on training, and regulatory-ready workflows.
“India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,” said Padraig McDonnell, CEO, Agilent Technologies.
“India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,” said Padraig McDonnell, CEO, Agilent Technologies.
Comprehensive Biopharma Solutions Under One Roof
The new Hyderabad facility will serve as an innovation and collaboration hub, focusing on biologics, biosimilars, and precision medicine. It offers end-to-end capabilities across:
- Chromatography and Mass Spectrometry
- Cell Analysis Technologies
- Laboratory Informatics
- Regulatory-Ready Workflow Integration
These resources will allow startups, academic researchers, and global pharma companies to simulate real-world lab environments, validate solutions, and accelerate time-to-market for life-saving therapeutics.
Accelerating Local Innovation, Supporting ‘Make in India’
The center is also a vital pillar in Agilent’s strategy to enable local innovation and deepen customer partnerships. Through hands-on training, aligned with global regulatory standards, and access to the latest instrumentation, the facility fosters stronger industry-academia collaboration and prepares India’s workforce for future-ready healthcare challenges.
“This new experience center reinforces our support for the ‘Make-in-India’ initiative by nurturing local talent and delivering scalable, affordable, and sustainable solutions,” McDonnell noted.
“This new experience center reinforces our support for the ‘Make-in-India’ initiative by nurturing local talent and delivering scalable, affordable, and sustainable solutions,” McDonnell noted.
Hyderabad: A Global Biopharma Hub
With nearly one-third of India’s pharmaceutical production and 40% of its bulk drug exports, Telangana has emerged as a powerhouse in pharmaceutical and biotech innovation. Hyderabad’s mature life sciences ecosystem, with robust policy support, skilled talent, and global pharma presence, made it an ideal location for Agilent’s new center.
“The Agilent Biopharma Experience Center is a significant milestone that strengthens Telangana’s position as a global life sciences leader,” said Minister Sridhar Babu. “It reflects our focus on innovation and building a future-ready healthcare system.”
“The Agilent Biopharma Experience Center is a significant milestone that strengthens Telangana’s position as a global life sciences leader,” said Minister Sridhar Babu. “It reflects our focus on innovation and building a future-ready healthcare system.”
Strengthening Global Innovation Roadmap
Earlier this year, Agilent also launched its India Solution Center in Manesar. Together with the Hyderabad center, these initiatives position India as a strategic innovation hub in Agilent’s global roadmap.
“We are already working with many of India’s leading biopharma companies,” said McDonnell. “This new center will help us co-create solutions that address the evolving needs of Indian and global markets.”
“We are already working with many of India’s leading biopharma companies,” said McDonnell. “This new center will help us co-create solutions that address the evolving needs of Indian and global markets.”
Visit Our News section and follow us on LinkedIn and Twitter
